ORCL:NYSEOracle Corporation Analysis
Data as of 2026-09-09 - not real-time
$160.65
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Oracle Corporation is priced at $160.65, and its moving averages give no clean directional read — the structure is neutral. The last 30 days have gained 33.9%. With RSI at 61.3 the momentum picture is approaching overbought, alongside a bullish MACD signal. The recent range runs from support at $137.43 up to resistance at $170.70.
Multiples put this in fair territory: 27.6 times earnings against the sector's 33.2. Consensus targets land 50.3% above where the shares trade now. Revenue is growing at 20.6% on a 25.4% profit margin. The 1.23% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 54.0%, a beta of 2.06 and a maximum drawdown of 65.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 3/10.
Multiples put this in fair territory: 27.6 times earnings against the sector's 33.2. Consensus targets land 50.3% above where the shares trade now. Revenue is growing at 20.6% on a 25.4% profit margin. The 1.23% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 54.0%, a beta of 2.06 and a maximum drawdown of 65.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 3/10.
Top Market Events
Oracle reports Q1 FY2027 earnings on September 10.Oracle Corporation remains a Buy due to its OCI capacity execution, contracted AI demand, and improving liquidity.Oracle is gaining an encouraging earnings outlook as it transforms its position in the market to become a major...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 168.17
- MACD momentum is positive
- 30-day price change of +33.9%
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 27.6 versus sector average of 33.2
- Trading below the 200-day average of 168.17
- Analyst targets imply +50.3% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 27.6 versus sector average of 33.2
- Analyst targets imply +50.3% versus the current price
- Profit margin of 25.4% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth20.60%
Profit Margin25.37%
P/E Ratio27.6
ROE53.38%
ROA6.50%
Debt/Equity388.87
P/B Ratio12.3
Op. Cash Flow$32.0B
Free Cash Flow$-24536750080
Industry P/E33.2
Technical Analysis
TrendNeutral
RSI61.3
Support$137.43
Resistance$170.70
MA 20$149.64
MA 50$140.38
MA 200$168.17
MACDBullish
VolumeStable
Fear & Greed Index92.79
Valuation
Fair Value$179.97
Target Price$241.43
Upside/Downside50.28%
GradeFair
TypeGrowth
Dividend Yield1.23%
Risk Assessment
Beta2.06
Volatility53.98%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.